Developing countries ask for easy access to vaccines patent

More than 120 countries including India and South Africa have asked for a waiver on vaccine patents. The nations are seeking to help their citizens if these patents are suspended. 

Developing nations seek vaccine patent suspension 

More than 135 nations have not been given any dose of the COVID-19 drugs. These statistics were given by the UN during a statement on Wednesday. Also, South Africa, India, and some other nations have asked the World Trade Organization to remove patients for coronavirus vaccines because these impede them from treating their citizens.

This call was first made by these countries around November last year, and it seems the UN is not doing anything about it. The World Trade Organization has been advised to waive the trade agreement's policy which will let health products be accessible by developing countries. After the calls by India and South Africa, more than 120 nations have joined the call. 

While supporting the request for a vaccine waiver, the WHO director Tedros Adhanom has said that '', if these waivers cannot be given now, when will it ever be given? These are difficult times and these situations need urgent solutions, a waiver is needed. 

South Africa and India championing the fight for COVID-19 patents removal 

The duo of South Africa and India have tendered a paper encouraging the waiving of intellectual rights. This paper aims to help these developing nations transfer technology and help in vaccine development and other crucial medical equipment. 

In February, more than 450 organizations had called on the US President to approve a waiver, while more than 110 EU members have called on the European Union leadership to stop its opposition to the waiver.  

The African Union has also joined calls for the immediate waiver of this vaccine patent to allow every nation to have the best chance of survival. Many have said that Some EU nations and the US are not so keen on the waiver because it benefits their selfish nature.